Endocrine tumours of the gastrointestinal tract. Somatostatin receptors as tools for diagnosis and therapy: molecular aspects.
Somatostatin is a neuropeptide that acts as an endogenous inhibitor of various cellular functions including endocrine and exocrine secretions and the proliferation of normal and tumour cells. Its action is mediated by a family of G-protein-coupled receptors (sst1-sst5) that are widely distributed in normal and tumour cells. Gastroenteropancreatic endocrine tumours express multiple somatostatin receptors, sst2 being clearly predominant. These receptors represent the molecular basis for the clinical use of somatostatin analogues in the treatment of endocrine tumours and their in vivo localisation. This review covers current knowledge in somatostatin receptor biology and signalling.
Guillermet-Guibert
Julie
J
IFR31, Institut Louis Bugnard, BP 84225, INSERM U531, Toulouse, France.
Lahlou
Hicham
H
Pyronnet
Stéphane
S
Bousquet
Corinne
C
Susini
Christiane
C
D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D006801:Humans; D007205:Indium Radioisotopes; D048370:MAP Kinase Kinase 2 / Q000502:physiology; D018919:Neovascularization, Physiologic / Q000502:physiology; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy; D017481:Receptors, Somatostatin / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D013004:Somatostatin / Q000031:analogs & derivatives; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D042461:Vascular Endothelial Growth Factor A; D013004:Somatostatin; D048370:MAP Kinase Kinase 2; C081788:pentetreotide